Orlistat in the prevention of diabetes in the obese patient

Vascular Health and Risk Management

Volumn 4, Issue 2, 2008, Pages 325-336

  Mancini, Marcio C ^a,b   Halpern, Alfredo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Diabesity; Metabolic syndrome; Obesity; Orlistat; Prevention; Type 2 diabetes mellitus

Indexed keywords

AMLODIPINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CONJUGATED ESTROGEN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; MEDROXYPROGESTERONE ACETATE; METFORMIN; NIFEDIPINE; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRANDOLAPRIL PLUS VERAPAMIL; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN;

ABNORMAL LABORATORY RESULT; BODY MASS; CLINICAL TRIAL; DIETARY INTAKE; DRUG ELIMINATION; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME INHIBITION; FOOD COMPOSITION; GASTROINTESTINAL DISEASE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; LACTONES; LIFE STYLE; OBESITY; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 44049087524     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981-97. Erratum in: JAMA, 2003 289:178. JAMA, 2004 291:2196.
2. [ADA] American Diabetes Association. 2003. Economic costs of diabetes in the U.S. in 2002. Diabetes Care, 26:917-32.
3. American Diabetes Association Clinical Practice Recommendations. 2004. Prevention or delay of type 2 diabetes. Diabetes Care, 27(Suppl 1): S47-54.
4. Anderson Jr DC. 2005. Pharmaological prevention or delay of type 2 diabetes mellitus. Ann Pharmacother, 39:102-9.
5. Andrulionyte L, Zacharova J, Chiasson JL, et al. STOP-NIDDM Study Group. 2004. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia, 47:2176-84.
6. [APCSC] Asia Pacific Cohort Studies Collaboration. 2007. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev, 8:191-6.
7. Bays H. 2005. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther, 3:393-404.
8. Bays H, Blond L, Rosenson R. 2006. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther, 4:871-95.
9. Benjamin SM, Valdez R, Geiss LS, et al. 2003. Estimated number of adults with prediabetes in the U.S. in 2000. Diabetes Care, 26:645-9.
10. Borst SE. 2004. The role of TNF-alpha in insulin resistance. Endocrine, 23:177-82.
11. Boyko EJ, Fujimoto WY, Leonetti DL, et al. 2000. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care, 23:465-71.
12. Brandberg J, Lönn L, Peltonen M, et al. 2003. Body composition changes during 4 years of treatment with orlistat vs placebo (The XENDOS study). Int J Obes, 27(Suppl 1):S100.
13. Buchanan TA, Xiang AH, Peters RK, et al. 2002. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 51:2796-803.
14. Calles-Escandon J, Cipolla M. 2001. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev, 22:36-52.
15. Carriere F, Renou C, Ransac S, et al. 2001. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol, 281:G16-28.
16. Chan JM, Rimm EB, Colditz GA, et al. 1994. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care, 17:961-9.
17. Chiasson JL, Josse RG, Gomis R, et al. 2003. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP NIDDM trial. JAMA, 290:486-94.
18. Colditz GA, Willet WC, Rotznitzky A, et al. 1995. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med, 122:481-6.
19. Conigrave KM, Hu BF, Camargo CA, et al. 2001. A prospective study of drinking pattern in relation to risk of type 2 diabetes among men. Diabetes, 50:2390-5.
20. Corpeleijn E, Saris WH, Jansen EH, et al. 2005. Postprandial interleukin-6 release from skeletal muscle in men with impaired glucose tolerance can be reduced by weight loss. J Clin Endocrinol Metab, 90:5819-24.
21. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:1004-1010.
22. Dahlof B, Sever PS, Poulter NR, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366:895-906.
23. Damci T, Yalin S, Balci H, et al. 2004. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care, 27:1077-80.
24. Dandona P, Aljada A, Bandyopadhyay A. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol, 25:4-7.
25. Davidson MH, Hauptman J, Di Girolamo M, et al. 1999. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA, 281:235-42.
26. Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. 2004. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin, 20:1393-401.
27. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368:1096-105.
28. Eddy DM, Schlessinger L, Kahn R. 2005. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med, 143:251-64.
29. Edelstein SL, Knowler WC, Bain RP, et al. 1997. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes, 46:701-10.
30. Eldor R, Raz I. 2006. Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract, 74(2 Suppl):S3-8.
31. Eriksson KF, Lindgarde F. 1991. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia, 34:891-8.
32. [ECDCDM] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes, 20:1183-97.
33. Ferrannini E, Barrett EJ, Bevilacqua S, et al. 1983. Effect of fatty acids on glucose production and utilization in man. J Clin Invest, 72:1737-47.
34. Ferreira SR, Lerario DD, Gimeno SG, et al. 2002. Obesity and central adiposity in Japanese immigrants: role of the Western dietary pattern. J Epidemiol, 12:431-8.
35. Foxcroft DR. 2005. Orlistat for the treatment of obesity: cost utility model. Obes Rev, 6:323-8.
36. Freeman DJ, Norrie J, Sattar N, et al. 2001. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 103:357-62.
37. Fung TT, Hu FB, Pereira MA, et al. 2002. Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am J Clin Nutr, 76:535-40.
38. Fung TT, Schulze M, Manson JE, et al. 2004. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med, 164:2235-40.
39. Gruber A, Nasser K, Smith R, et al. 2006. Diabetes prevention: is there more than lifestyle changes? Int J Clin Pract, 60:590-4.
40. Guerciolini R. 1997. Mode of action of orlistat. Int J Obes Relat Metab Disord, 21:S12-23.
41. Halpern A, Mancini MC, Suplicy H, et al. 2003. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab, 5:180-8.
42. Halpern A, Mancini MC. 2005. Diabesity: are weight loss medications effective? Treat Endocrinol, 4:65-74.
43. Hansson L, Lindholm LH, Niskanen L, et al. 1999. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 353:611-6.
44. [HOPE] Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet, 355:253-9.
45. Heymsfield SB, Segal KR, Hauptman J, et al. 2000. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med, 160:1321-6.
46. Hoffmann J, Spengler M. 1994. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care, 17:561-6.
47. Hoffmann J, Spengler M. 1997. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med, 103:483-90.
48. Hollander PA, Elbein SC, Hirsch IB, et al. 1998. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care, 21: 1288-1294.
49. Hsieh CJ, Wang PW, Liu RT, et al. 2005. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract, 67:78-83.
50. Hu FB, Sigal RJ, Rich-Edwards JW, et al. 1999. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA, 282:1433-9.
51. Hu FB, Manson JE, Stampfer MJ, et al. 2001. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med, 345:790-7.
52. [IDF] International Diabetes Federation. 2006. Diabetes prevalence [online]. Accessed 12 October 2006. URL: http://www.idf.org/home/ index.cfm?node=264.
53. Isomaa B, Almgren P, Tuomi T, et al. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24:683-99.
54. James WPT, Rigby N, Leach R. 2004. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil, 11:3-8.
55. James WPT. 2005. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J, 7(Suppl): L44-8.
56. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363:2022-31.
57. Kanaya AM, Herrigton D, Vittinghoff E, et al. for the Heart and Estrogen/ Progestin Replacement Study (HERS). 2003. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med, 138:1-9.
58. Keating GM, Jarvis B. 2001. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drugs, 61:2107-19; discussion 2120-1.
59. Kelley DE, Williams K, Price J, et al. 2001. Plasma fatty acids, adiposity and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab, 86:5412-19.
60. Kelley DE, Bray GA, Pi-Sunyer FX, et al. 2002. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care, 25:1033-41. Erratum in: Diabetes Care, 26:971.
61. Kelley DE, Kuller LH, McKolanis TM, et al. 2004. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care, 27:33-40.
62. Kissebah AH, Krakower GR. 1994. Regional adiposity and morbidity. Physiol Rev, 74:761-811.
63. Knowler WC, Pettitt DJ, Saad MF, et al. 1990. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diab Metab Rev, 6:1-27.
64. Knowler WC, Barrett-Connor E, Fowler SE, et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403.
65. Kosaka K, Noda M, Kuzuya T. 2005. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract, 67:152-62.
66. Kriska AM, Pereira MA, Hanson RL, et al. 2001. Association of physical activity and serum insulin concentrations in two populations at high risk for type 2 diabetes but differing by BMI. Diabetes Care, 24:1175-80.
67. Lacey LA, Wolf A, O'shea D, et al. 2005. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond). 29:975-82.
68. Lindgren P, Lindstrom J, Tuomilehto J, et al. DPS Study Group. 2007. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care, 23:177-83.
69. Lindholm LH, Persson M, Alaupovic P, et al. 2003. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens, 21:1563-74.
70. Lopez-Ridaura R, Willet CW, Rimm BE, et al. 2004. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care, 27:134-9.
71. Lovejoy JC. 1999. Dietary fatty acids and insulin resistance. Curr Atheroscler Rep, 1:215-20.
72. Maetzel A, Ruof J, Covington M, et al. 2003. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics, 21:501-12.
73. Mancia G, Brown M, Castaigne A, et al. 2003. INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 41:431-6.
74. Marshall JA, Hamman RF, Baxter J. 1991. High-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: The San Luis Valley Diabetes Study. Am J Epidemiol, 134:590-603.
75. Mather HM, Keen H. 1985. The Douthall Diabetes survey: prevalence of known diabetes in Asians and Europeans. Br Med J, 291:1081-4.
76. Meier JJ, Gallwitz B, Nauck MA. 2003. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs, 17:93-102.
77. Meyer KA, Kushi LH, Jacobs DR Jr, et al. 2000. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr, 71:921-30.
78. Miles JM, Leiter L, Hollander P, et al. 2002. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care, 25(7): 1123-8. Erratum in: Diabetes Care, 25(9):1671.
79. Mokdad AH, Ford ES, Bowman BA, et al. 2000. Diabetes trends in the U.S.: 1990-1998. Diabetes Care, 23:1278-83.
80. Monteiro CA, Benicio MHA, Conde WL, et al. 2000. Shifting obesity trends in Brazil. Eur J Clin Nutr, 43:341-6.
81. Narayan KMW, Boyle JP, Thompson TJ, et al. 2003. Lifetime risk for diabetes mellitus in the United States. JAMA, 290:1884-90.
82. Nauck MA, Meier JJ. 2005. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept, 128:135-48.
83. Norris SL, Chowdhury FM, Van Le K, et al. 2006. Effectiveness of community health workers in the care of persons with diabetes. Diabet Med, 23:544-56.
84. Padwal R, Laupacis A. 2004. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care, 27:247-55.
85. Padwal R, Majumdar SR, Johnson JA, et al. 2005. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care, 28:736-44.
86. Pan XR, Li GW, Hu YH, et al. 1997. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care, 20:537-44.
87. Park KS. 2004. Prevention of type 2 diabetes mellitus from the viewpoint of genetics. Diabetes Res Clin Pract, 66(Suppl 1):S33-5.
88. Park KS, Shin HD, Park BL, et al. 2006a. Putative association of peroxisome proliferator-activated receptor gamma co-activator 1beta (PPARGC1B) polymorphism with type 2 diabetes mellitus. Diabet Med, 23:635-42.
89. Park KS, Shin HD, Park BL, et al. 2006. Polymorphisms in the leptin receptor (LEPR) - putative association with obesity and T2DM. J Hum Genet, 51:85-91.
90. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. 2003. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA, 290:2805-16.
91. Perry IJ, Wannamethee SG, Walker MK, et al. 1995. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. Br Med J, 310:560-4.
92. Piatti PM, Monti LD, Davis SN, et al. 1996. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM subjects. Diabetologia, 1996:103-12.
93. Pontiroli AE, Folli F, Paganelli M, et al. 2005. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care, 28:2703-9.
94. Prisant LM. 2004. Preventing type II diabetes mellitus. J Clin Pharmacol, 44:406-13.
95. Randle PJ, Garland PB, Hales CN, et al. 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 13:785-9.
96. Randle PJ. 1998. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev, 14:263-83.
97. Reaven GM. 1988. The role of insulin resistance in human disease. Diabetes, 37:1595-1607.
98. Retnakaran R, Hanley AJ, Zinman B. 2006. Does hypoadiponectinemia explain the increased risk of diabetes and cardiovascular disease in South asians? Diabetes Care, 29:1950-4.
99. Richelsen B, Tonstad S, Rössner S, et al. 2007. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study Diabetes Care, 30:27-32.
100. Rossner S, Sjöström L, Noack R, et al. 2000. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res, 8:49-61.
101. Samuelsson L, Gottsater A, Lindgarde F. 2003. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab, 5:195-201.
102. Santomauro AT, Boden G, Silva ME, et al. 1999. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes, 48:1836-41.
103. Satterfield DW, Volansky M, Caspersen CJ, et al. 2003. Community-based lifestyle interventions to prevent type 2 diabetes. Diabetes Care, 26:2643-52.
104. Saydah SH, Loria CM, Eberhardt MS, et al. 2001. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care, 25:447-53.
105. Scheen AJ, Ernest P. 2002. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab, 28:437-45.
106. Scheen AJ. 2003. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs, 63:933-51.
107. Schulz LO, Bennett PH, Ravussin E, et al. 2006. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the US. Diabetes Care, 29:1866-71.
108. Sjöström L, Rissanen A, Andersen T, et al. European Multicentre Orlistat Study Group. 1998. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352:167-72.
109. Sjöström L, Lindroos AK, Peltonen M, et al. 2004. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med, 351:2683-93.
110. Swinburn BA, Metcalf PA, Ley SJ. 2001. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care, 24:619-24.
111. Tan K, Tso A, Tam S, et al. 2002. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med, 19:944-8.
112. Tenenbaum A, Motto M, Fisman EZ, et al. 2004. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation, 109:2197-202.
113. Thomsen C, Storm H, Holst JJ, et al. 2003. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr, 77:605-11.
114. Tong PC, Lee ZS, Sea MM, et al. 2002. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med, 162:2428-35.
115. Torgerson JS, Hauptman J, Boldrin MN, et al. 2004. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27:155-61. Erratum in: Diabetes Care, 2004 27:856.
116. Tsai AG, Wadden TA. 2005. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med, 142:56-66.
117. Tuomilehto J, Lindstron J, Eriksson JG, et al. 2001. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 344:1343-50.
118. Tuomilehto J. 2005. Primary prevention of type 2 diabetes: lifestyle intervention works and saves money, but what should be done with smokers? Ann Intern Med, 142:381-3.
119. [UKPDS] United Kingdom Prospective Diabetes Study Group. 1995. UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes. Diabetes, 44:1249-58.
120. Uwin N, Shaw J, Zimmet P, et al. 2002. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diab Med, 19:708-23.
121. Valsamakis G, McTernan PG, Chetty R, et al. 2004. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism, 53:430-4.
122. Van Dam RM, Rimm EB, Willett WC, et al. 2002. Dietary patterns and risk of type 2 diabetes mellitus in US men. Ann Intern Med, 136:201-9.
123. Van Dam RM, Hu FB. 2005. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA, 294:97-104.
124. Vilsboll T, Krarup T, Sonne J, et al. 2003. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab, 88:2706-13.
125. Wang Y, Mi J, Shan XY, et al. 2007. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond), 31:177-88.
126. Weyer C, Bogardus C, Mott DM, et al. 1999. The natural hystory of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investig, 104:787-94.
127. Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27:1047-53.
128. Williams KV, Mullen ML, Kelley DE, et al. 1998. The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care, 21:2-8.
129. Wing RR, Koeske R, Epstein LH, et al. 1987. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med, 147:1749-53.
130. Wing RR, Shoemaker M, Marcus MD, et al. 1990. Variables associated with weight loss and improvements in glycemic control in type II diabetic patients in behavioral weight control programs. Int J Obes, 14:495-503.
131. [WHO] World Health Organization. 2000. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. Geneva: World Health Organization.
132. Wu SI, Chou P, Tsai ST. 2001. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol, 54:117-20.
133. Xu G, Stoffers DA, Habener JF, et al. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 48:2270-6.
134. Yusuf S, Ostergren JB, Gerstein HC, et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. 2005. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation, 112:48-53. Erratum in: Circulation, 112:e292.
135. Zacharova J, Chiasson JL, Laakso M; STOP-NIDDM Study Group. 2005a. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP+276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes, 54:893-9.
136. Zacharova J, Todorova BR, Chiasson JL, et al. STOP-NIDDM Study Group. 2005b. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. J Intern Med, 257:185-93.
137. Zhang Y, Howard BV, Cowan LD, et al. 2002. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women: the Strong Heart study. Diabetes Care, 25:500-4.
138. Zhi J, Melia AT, Eggers H, et al. 1995. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol, 35:1103-8.